Compare Abeona Therapeutics Inc (ABEO) vs iShares 20 Plus Year Treasury Bond ETF (TLT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs iShares 20 Plus Year Treasury Bond ETF — how do they compare? Abeona Therapeutics Inc trades at $6.36 (market cap $425.47M), while iShares 20 Plus Year Treasury Bond ETF trades at $82.59. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, iShares 20 Plus Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| ABEO | TLT | |
|---|---|---|
Market Cap | $425.47M | — |
Sector | Health | — |
52-Week High | $7.46 | $92.06 |
52-Week Low | $4.17 | $82.05 |
Enterprise Value | $280.37M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.46, up 0.81% today, with a bullish technical outlook supported by moving averages but overbought RSI signals. The company reported Q2 2026 revenue of $11.4 million, missing EPS estimates, yet maintains strong profitability margins and low valuations. Recent news highlights operational challenges with ZEVASKYN rollout but positive developments like CMS NTAP status.
Outlook is mixed: analyst consensus is bullish with 67% buy ratings, but risks include execution setbacks and shareholder investigations. Investment opportunity lies in growth potential if operational issues resolve, though high volatility and negative cash flows from operations pose near-term headwinds.
TLT, the iShares 20+ Year Treasury Bond ETF, trades at $82.11, down 0.1% on the day, with a bearish technical signal driven by moving averages. Recent news highlights pressure from rising Treasury yields and U.S. debt nearing $40 trillion, while institutional buying by Ferguson Shapiro LLC (37,900 shares, SEC filing August 10, 2026) provides some support. Dividend payments remain consistent, with the latest at $0.34 paid on June 4, 2026.
Outlook is cautious due to macroeconomic headwinds like inflation and potential Fed rate hikes, which could push yields higher and pressure TLT's price. The ETF's large AUM of $42.5 billion offers liquidity, but investors face interest rate risk amid bearish technicals and neutral oscillators.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About iShares 20 Plus Year Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index. The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity greater than or equal to twenty years.
Read more on TLT →
